Q1,Q2,Q3,Q4,Q5,Q6,Q7,Q8,Q9,Q10,Q11,Q12,Q13,Q14,Q15,Q16,Q17,Q18,Q19,Q20,source_file
Ahn 2020,Causal Inference between Rheumatoid Arthritis and Breast Cancer in East Asian and European Population: A Two-Sample Mendelian Randomization,Cancers,2020,Two-sample MR,"SNPs from six genome-wide association studies (GWAS) targeting RA in an East Asian population, and GWAS-summary results from the BBJ, BCAC, and CIMBA for breast cancer",25,Rheumatoid Arthritis,Breast Cancer,1,1,Six different GWAS targeting RA in an East Asian population,"BBJ (BioBank Japan), BCAC (Breast Cancer Association Consortium), and CIMBA (Consortium of Investigators of Modifiers of BRCA1/2)",The East Asian RA GWAS included six different studies with sample sizes ranging from 100 to 7907 RA cases and controls varying proportionally .,"BCAC: 122,977 cases and 105,974 controls; CIMBA: 15,252 BRCA1 and 8211 BRCA2 carriers",East Asian (Korean and Japanese)【4:6†source】,European【4:6†source】,Yes,"East Asia, Europe","R, Mendelian randomization package",#1 - Ahn 2020.pdf
Aoki 2022,Shared genetic components between metabolic syndrome and schizophrenia: Genetic correlation using multipopulation data sets,Psychiatry and Clinical Neurosciences,2022,Two-sample MR,"SNPs involved in the 1000 Genomes Project and HapMap Projects, with a minor allele frequency ≥ 1%, and INFO ≥0.9",NA,"Metabolic syndrome traits (BMI, HDL-C, blood sugar, triglycerides, systolic blood pressure, CRP)",Schizophrenia (SCZ),1,1,JENGER database provided by Biobank Japan,"PGC for EUR samples, PGC Asia for EAS samples","EAS: 24,504 (SCZ patients) and 42,770 (controls), EUR: Varies with trait, up to 361,194 samples","EAS: 24,504 (SCZ patients) and 42,770 (controls), EUR: Varies with trait, up to 361,194 samples",East Asian,European,Yes,"East Asia, Europe","TwoSample MR, LDSC software",#3 - Aoki 2022.pdf
AuYeung 2023,Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians,International Journal of Epidemiology,2023,Two-sample MR,"Genetic predictors of ALT, liability to NAFLD, AST, liver MRI cT1, proton density fat fraction, 195 ALT instruments, 228 AST instruments【4:9†source】","ALT: 195, AST: 228, cT1: 5, PDFF: 4【4:9†source】","ALT (alanine aminotransferase), liability to NAFLD (non-alcoholic fatty liver disease), AST (aspartate transaminase), liver MRI cT1, proton density fat fraction【4:0†source】","Cardiovascular diseases (CVD), type 2 diabetes (T2D), coronary artery disease (CAD) stroke, atrial fibrillation, heart failure【4:6†source】",5,6,"Neale Lab in the UK Biobank, Million Veteran Program, UK Biobank for cT1 and PDFF【4:4†source】","DIAMANTE consortium, MAGIC, CARDIoGRAM, MEGASTROKE, HERMES consortium【4:6†source】","GWAS for ALT: 344,292 participants; liability to NAFLD: 164,197; cT1 and PDFF: 14,440【4:4†source】","DIAMANTE consortium for T2D: existing samples of 977,320; GWAS for CVD: existing samples of 520K-1M; heart failure: existing samples from HERMES consortium【4:6†source】",European【4:4†source】,"European, East Asian【4:19†source】",Yes,"UK, Japan【4:19†source】","TwoSampleMR, R【4:19†source】",#4 - AuYeung 2023.pdf
